The company got a big shot in the arm on July 12, when the U.S. Food and Drug Administration granted fast-track status to the Canadian company's Fluviral flu vaccine.
Yesterday, the Food and Drug Administration granted it fast-track status, which should make it easier for Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) to file all the paperwork necessary for approval.
The U.S. Food and Drug Administration has granted BioCryst "fast track" status for its Peramivir trials because it may work in treating avian influenza.